Turning patient journeys into real-world health intelligence
Cohorta AI combines an intelligent patient companion with aggregated, anonymized, continuous insights, for pharma, medical centers, insurers, government health departments and health funds, in Israel and worldwide.
Patient journey, stages
Unique patients per stage · k≥10 · aggregated, anonymized
Journey signals
sample anonymized stream
Platform preview · illustrative sample data, not real patients
A privacy-first foundation for the entire patient journey
Design for Long-Term Patient Support
Supporting patients throughout the entire disease journey, from diagnosis and monitoring to treatment, remission, and ongoing follow-up.
Preparing for Multi-Center Patient Intelligence
Building the foundation for future aggregation of anonymized patient journey insights across healthcare providers, patient communities, and treatment pathways.
Privacy-First Architecture
Designed with patient privacy, informed consent, and responsible use of health information at its core.
Supporting patients across every phase of the CLL journey
Diagnosis
The moment of diagnosis: a first explanation of what CLL is, and the first answers.
Active monitoring
Monitoring the disease while maintaining quality of life.
Treatment Initiation
Helping patients navigate treatment decisions.
Active Treatment
Supporting symptom tracking, adherence and education.
MRD Monitoring
Helping patients understand monitoring results.
Remission
Returning to a healthy routine, with support that continues after treatment.
Follow-up & relapse
Long-term follow-up, and if the disease returns, steady support into the next line.
A warm front door for the patient. An intelligence engine for the health system.
Eight intelligence layers on one patient spine
No competitor combines all eight on one longitudinal spine. That is the moat.
Real-world patient signals
Symptoms, emotional state and adherence, captured continuously, with consent, anonymized.
Longitudinal journey intelligence
From diagnosis through watch-and-wait and treatment to MRD-negative and retreatment.
Emotional & behavioral monitoring
Distress and behavior shifts as an early proxy for clinical change.
Personalized education
Evidence-based content by journey stage, in the patient's language.
Clinical-trial awareness
Eligibility matching and surfacing relevant research pathways.
Early-intervention signals
Lymphocyte doubling, hemoglobin decline and iwCLL triggers.
Aggregated health-org intelligence
An anonymized picture for pharma, hospitals, payers and government.
Continuous RWE generation
Every interaction becomes aggregate evidence, with no PII.
One anonymized intelligence, for every health-system stakeholder
Pharma & life sciences
Real-world evidence on treatment adoption, persistence, switching and outcomes across the patient journey.
Medical centers & hospitals
Operational clinical intelligence for care teams, who to call first, where the risk is, how to prioritize.
Insurers & payers
Real cost-effectiveness, utilization patterns and outcomes, an evidence base for coverage decisions.
Government health departments
Aggregate population view for policy-making, resource planning and national quality assessment.
Health funds (Kupot Holim)
Insights into the member journey, early intervention and patient-experience improvement across the continuum.
Researchers & academia
Longitudinal, anonymized, precise cohorts for real-world outcomes research questions.
Privacy is not a feature. It is the foundation.
Explicit per-category consent. No PII in any table. No drill-through to a single patient. A k≥10 floor and differential privacy. Every access logged. Consent revocation purges within 24 hours.
Elad Keren
Founder & CEO · Cohorta AI
"I am myself one of the first Venetoclax-treated CLL patients in Israel, in a deep MRD-negative remission that is still holding, for over six years now."
The platform was born from a personal journey: real-world evidence, the shift from chemo to targeted therapy, and a deep understanding of what a patient truly needs, all the way through.
Read the full story →Let's build patient-journey intelligence together
A pilot, a research partnership, or an enterprise rollout, we would love to talk.